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Mutations in the gene TARDBP, which encodes TAR DNA-binding protein 43 (TDP-
43), are a rare cause of familial forms of amyotrophic lateral sclerosis (ALS) and
frontotemporal dementia (FTD). While the majority of mutations are found in the
C-terminal glycine-rich domain, an alanine to valine amino acid change at position
90 (A90V) in the bipartite nuclear localization signal (NLS) of TDP-43 has been
described. This sequence variant has previously been shown to cause cytoplasmic
mislocalization of TDP-43 and decrease protein solubility, leading to the formation of
insoluble aggregates. Since the A90V mutation has been described both in patients
as well as healthy controls, its pathogenic potential in ALS and FTD remains unclear.
Here we compare properties of overexpressed A90V to the highly pathogenic M337V
mutation. Though both mutations drive mislocalization of the protein to the cytoplasm to
the same extent, M337V produces more significant damage in terms of protein solubility,
levels of pathogenic phosphorylation, and formation of C-terminal truncated protein
species. Furthermore, the M337V, but not the A90V mutant, leads to a downregulation of
histone deacetylase 6 and Ras GTPase-activating protein-binding protein. We conclude
that in the absence of another genetic or environmental ‘hit’ the A90V variant is not
sufficient to cause the deleterious phenotypes associated with ALS and FTD, despite
prominent cytoplasmic protein relocalization of TDP-43.
Keywords: amyotrophic lateral sclerosis (ALS), TAR DNA-binding protein 43 (TDP-43), neurodegenerative
diseases, frontotemporal dementia, mutation, protein misfolding disease
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fast progressing neurodegenerative disorder associated
with atrophy of upper and/or lower motor neurons leading to muscle wasting due to denervation.
It is the third most frequently occurring neurodegenerative disease after Alzheimer’s disease and
Parkinson’s disease (Hirtz et al., 2007). Death usually occurs within 2–3 years after diagnosis as a
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result of respiratory failure (Chio et al., 2011). Frontotemporal
dementia (FTD) on the other hand is characterized by
degeneration of neurons in the frontal and temporal lobes
and is associated with impairment of cognitive abilities and
language, as well as behavioral changes (Bang et al., 2015).
Today, both diseases fall under the umbrella term of TDP-43
proteinopathies, in reference to the occurrence of cytoplasmic
inclusions of the TAR DNA-binding protein 43 (TDP-43) in glial
and neuronal cells: 97% of ALS as well as almost 50% of FTD
cases present with such TDP-43-positive inclusions (Cairns et al.,
2007; Mackenzie et al., 2007). In this pathological state, TDP-
43 is found ubiquitinated, truncated, highly phosphorylated and
aggregated (Arai et al., 2006; Neumann et al., 2006).
TAR DNA-binding protein 43 is a ubiquitously expressed
RNA- and DNA-binding protein. In the central nervous system,
TDP-43 binds over 6000 RNA targets. It has been shown to
regulate the levels of 600 mRNA species and the alternative
splicing of over 950 species (Polymenidou et al., 2011). RNA
binding is mediated by two RNA recognition motifs, RRM1 and
RRM2. In addition, the protein harbors a nuclear export signal
(NES) as well as a bipartite NLS, and a C-terminal prion-like
glycine-rich domain (Figures 1A,C) (Buratti and Baralle, 2001;
Winton et al., 2008a). Mutations in the TDP-43 gene TARDBP
in ALS were first described in 2008 (Gitcho et al., 2008; Kabashi
et al., 2008; Sreedharan et al., 2008; Van Deerlin et al., 2008). The
frequency of TDP-43 mutations is 1–5% in both sporadic and
familial forms of ALS (Guerreiro et al., 2008; Kabashi et al., 2008;
Kuhnlein et al., 2008; Iida et al., 2012; Zou et al., 2012).
The vast majority of TARDBP mutations are missense
mutations, with all but three located in the C-terminal glycine-
rich domain (Buratti, 2015). Two mutations, P112H and D169G,
are located in the RRM1 domain (Kabashi et al., 2008; Buratti,
2015; Moreno et al., 2015). The third, an alanine to valine
substitution at residue 90 (A90V), is found between the bipartite
NLS (Winton et al., 2008b; Chiang et al., 2012). Winton et al.
(2008b) showed that the A90V mutation leads to aberrant
cytoplasmic localization and decreased solubility of TDP-43,
two pathological hallmarks of TDP-43 proteinopathies, in vitro.
Another study found that under stress conditions, induced
pluripotent stem cells with the A90V mutation obtained from
an FTD/ALS patient showed increased cell death, cytoplasmic
localization of TDP-43 and downregulation of microRNA-9
(Zhang et al., 2013). However, the variant has been described
both in FTD and ALS patients and control individuals (Guerreiro
et al., 2008; Kabashi et al., 2008; Sreedharan et al., 2008; Winton
et al., 2008b; Chiang et al., 2012). Further studies described
the occurrence of the A90V variant at a higher frequency in
Alzheimer’s disease patients compared to controls (Brouwers
et al., 2010; Vanden Broeck et al., 2015). Thus the detection of the
A90V variant in healthy controls combined with the biochemical
findings reported by Winton et al. (2008b) leave its pathogenic
nature unclear.
In this study, we compared the effects of the A90V variant
of TDP-43 to both wild-type (WT) and the M337V mutation, a
pathogenic mutation associated with familial ALS (Sreedharan
et al., 2008), in the SH-SY5Y neuroblastoma cell line. We provide
evidence that while the A90V amino acid change phenocopies the
M337V mutation in terms of cytoplasmic mislocalization, it does
not demonstrate such a severe phenotype in terms of formation
of insoluble high molecular weight aggregates and C-terminal
fragments, pathological phosphorylation or downregulation of
TDP-43 targets G3BP and histone deacetylase 6 (HDAC6). We
thus conclude that relocalization of TDP-43 from the nucleus
to the cytoplasm alone, while a classic pathological feature of
TDP-43 proteinopathies, is not in itself sufficient to cause the
complete cellular disease signature. Furthermore, we propose that
the A90V variant of TDP-43 could be a rare risk factor for ALS
that requires another “hit” for the development of the full-blown
disease pathology.
MATERIALS AND METHODS
Plasmids
All plasmids were purchased from and customized by Origene.
cDNA sequences were based on the accession number
NM_007375.3 for human TARDBP. The WT construct was
cloned into the pCMV6-AN-myc vector for expression
of N-terminally tagged WT or mutant TDP-43 protein.
Custom mutagenesis to generate the A90V (point mutation
c.269C>T) and M337V (point mutation c.1009A>G) TDP-43
amino acid substitutions were carried out by Origene. The
presence of each mutation was confirmed by DNA sequencing
performed by GENEWIZ (forward sequencing primer 5′-
GGACTTTCCAAAATGTCG-3′; reverse sequencing primer
5′-ATTAGGACAAGGCTGGTGGG-3′).
Cell Culture
SH-SY5Y cells were grown at 37◦C with 5% CO2 in a
humidified atmosphere in minimum essential medium (MEM;
Thermo Fisher Scientific) supplemented with L-glutamine, 10%
fetal bovine serum and 1% penicillin/streptomycin. Cells were
subcultured every 3–4 days. For immunofluorescence analysis,
cells were grown on glass coverslips coated with 1 mg/mL poly-
L-lysine (Sigma) in 24-well plates (Cellstar). For Western blot
analysis, cells were grown in 6-well plates (Costar). Cells were
transiently transfected using Fugene HD (Promega) following the
manufacturer’s instructions 24 h after seeding (Fugene HD:DNA
ratio 3:1). Total transfection time was 48 h.
Antibodies
The following antibodies were used for immunofluorescence
staining: rabbit N-terminal TDP-43 (1:500; 10782-2-AP,
Proteintech), mouse anti-myc 9E10 (1:200; Developmental
Studies Hybridoma Bank, 1:200: sc-40, Santa Cruz), mouse anti-
scaffold attachment factor B (SAFB) 6F7 (1:300; ab8060, Abcam),
mouse anti-protein-associated splicing factor (PSF) (1:50; P2860,
Sigma), mouse anti-ubiquitin P4D1 (1:50; sc-8017, Santa Cruz).
Anti-mouse and anti-rabbit secondary antibodies coupled to
Alexa-488, Alexa-555, and Alexa-568 were used for detection
(1:300; Thermo Fisher Scientific). For Western blot analysis,
the following antibodies were used: rabbit C- and N-terminal
TDP-43 (1:2,500; 12892-1-AP, 1:5,000; 10782-2-AP, Proteintech),
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FIGURE 1 | Composite nuclear magnetic resonance (NMR) structure of TAR DNA-binding protein 43 (TDP-43). (A) Human TDP-43 sequence illustrating
the nuclear localization sequence (NLS), nuclear export signal (NES), RNA recognition motifs (RRM1 and RRM2), glycine-rich domain, as well as the A90V and
M337V mutation sites, and the S409/S410 phosphorylation sites. (B) Available NMR solution structures for domains of TDP-43: PDB codes 2N4P, 2CQG, 1WF0,
2N2C (He et al., 2004; Suzuki et al., 2005; Lim and Song, 2015; Mompean et al., 2015; Lim et al., 2016; Mompean et al., 2016). Note that these structures – as well
as the available X-ray structures 4IUF, 4Y00, and 4Y0F (Kuo et al., 2014; Chiang et al., 2016) – do not span the entire sequence, and large portions are either
missing or poorly resolved, for example S90 in the largely unstructured terminus of 2CQG at the A90V site. (C) Composite TDP-43 schematic of available NMR
structures. While iterative homology modeling and loop building techniques were used, a suitable template structure spanning across multiple domains was not
found, and this composite structure should be considered as a schematic rather than a confident prediction of folding. Note that in this orientation the S409/S410
phosphorylation site is at the back of the structure near the N-terminus.
mouse S409/410 phospho-TDP-43 (1:2,000; CAC-TIP-PTD-
M01, Cosmo), mouse α-tubulin (1:15,000; ab80779, Abcam),
rabbit HDAC6 (1:1,000; 12834-1-AP, Proteintech), mouse G3BP
(1:1,000; 611126, BD Biosciences), mouse acetylated α-tubulin
(1:3,000; 12152, Cell Signaling Technologies), mouse GAPDH
6C5 (1:2,000: sc-32233, Santa Cruz). Anti-mouse and anti-rabbit
horseradish peroxidase-coupled secondary antibodies were
purchased from Jackson Immunoresearch (1:7,000).
Immunofluorescence Staining
Cells were washed in phosphate-buffered saline (PBS) and fixed
in 4% paraformaldehyde (in PBS) for 15 min followed by
permeabilization in 0.25% Triton-X (in PBS) for 10 min. Ten
percent normal goat serum (in PBS; Abcam) was used as a
blocking reagent. Cells were blocked for 1 h at room temperature
and incubated overnight at 4◦C in primary antibody solution.
The next day, cells were washed with PBS and incubated for 1 h
in secondary antibody solution. Coverslips were mounted with
Prolong Gold Antifade Mountant with DAPI (Thermo Fisher
Scientific). Image acquisition was performed using a Nikon
A1 confocal/Eclipse Ti inverted microscope system and NIS
Elements software (Nikon).
Sequential Extraction of Insoluble
Protein Aggregates
The extraction protocol was adapted from Cohen et al. (2012).
Cells were grown in 6-well plates and transfected 24 h after
seeding. After 48 h, transfected cells were lysed in 300 µL
radio-immunoprecipitation assay (RIPA) buffer supplemented
with 2 mM EDTA, 1 mM EGTA, protease inhibitors (Complete,
Roche), and phosphatase inhibitors (PhosStop, Roche). Lysates
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were sonicated 2x 15 s with 20% maximum amplitude and
centrifuged for 30 min at 100,000 × g and 4◦C (Beckman
Optima TLX ultracentrifuge with TLA100.3 rotor and Delrin
adaptors). The supernatant was collected as the RIPA-soluble
fraction. The pellet was washed in RIPA buffer and centrifuged
for an additional 30 min at 100,000 × g and 4◦C. The
supernatant was discarded and the pellet was re-extracted
in 100 µL urea buffer [7 M urea, 2 M thiourea, 30 mM
Tris pH 8.5, 4% 3-[(3-Cholamidopropyl) dimethylammonio]-1-
propanesulfonate (CHAPS, Sigma)]. The samples were sonicated
2x 15 s and centrifuged at room temperature for 30 min at
100,000 × g. The supernatant was collected as the urea-soluble
fraction.
Immunoblotting
Cells were lysed in RIPA buffer supplemented with 2 mM
EDTA, 1 mM EGTA, protease inhibitors (Complete, Roche)
and phosphatase inhibitors (PhosStop, Roche), and the protein
concentration was determined by bicinchoninic acid (BCA)
assay. RIPA and urea fractions obtained from sequential
extractions were diluted 1:1 with RIPA buffer. Proteins
were separated using standard Tris-glycine SDS-PAGE gels
(polyacrylamide concentrations 8% for HDAC6, all others 10%)
and transferred onto nitrocellulose (BioRad) or polyvinylidene
difluoride (PVDF; Millipore) membranes. All blocking and
antibody incubation steps were performed either in 5% milk
in Tris-buffered saline (TBS) supplemented with 0.1% Tween-
20 (TBS-T) or in 3% bovine serum albumin (BSA) in TBS-T.
Western blots were developed with enhanced chemiluminescent
substrates (ECL). Digital images were acquired with a ChemiDoc
MP imaging system (BioRad) and quantified with Image Lab 5
(BioRad). Where necessary, blots were stripped with stripping
buffer for 15 min (Restore, Thermo Fisher Scientific) and
reprobed with loading control antibodies.
Composite NMR Structure
The composite schematic of the full structure of human TDP-
43 was produced from the nuclear magnetic resonance (NMR)
structures 2N4P (Mompean et al., 2015, 2016), 2CQG (Suzuki
et al., 2005), 1WF0 (He et al., 2004), and 2N2C (Lim and Song,
2015; Lim et al., 2016) [obtained from the Research Collaboratory
for Structural Bioinformatics Protein Data Bank (RCSB PDB;
Berman et al., 2000)] via iterative homology modeling and
loop building using the Molecular Operating Environment
(MOE) software (Molecular Operating Environment [MOE],
2017).
Statistical Analysis
All data were expressed as mean ± standard error of the
mean (SEM). Statistical analyses were performed using GraphPad
Prism 6 software (San Diego, CA, USA). Normality was
established using the Shapiro–Wilk test. Mean differences
between groups were analyzed by one-way ANOVA and
Tukey’s multiple comparisons test. The threshold for statistical
significance was p ≤ 0.05. Experiments were replicated a
minimum of three times.
RESULTS
In silico Analysis of TDP-43 Protein and
Determining Whether It Can Predict the
Impact of Mutations on Protein Structure
Nuclear magnetic resonance and X-ray structural analysis of
individual domains of WT and mutant TDP-43 continue to
reveal insights into the relationships between disease-related
mutations and the biophysical stability of the protein. We
reasoned that assembling a three-dimensional model of TDP-
43 may help us predict the structural impact of the A90V
variant and support our in vitro efforts in elucidating its
effects. Thus, we attempted to collate all structural information
obtained from NMR and X-ray crystallography available in
the public domain and obtain a complete 3D model of TDP-
43 (Figure 1). However, structures including all domains
which might enable a comprehensive examination of the
effects of specific mutations on overall structure and stability
are challenging and not yet realized. The human TDP-43
sequence (Figure 1A) and NMR structures (Figure 1B) in
Figure 1 highlight the NLS, NES, RRM1, RRM2, glycine-
rich domain, as well as the A90V and M337V mutation
sites and the S409/S410 phosphorylation site (He et al., 2004;
Suzuki et al., 2005; Kuo et al., 2014; Lim and Song, 2015;
Mompean et al., 2015, 2016; Chiang et al., 2016; Lim et al.,
2016). The piecewise solutions of NMR and X-ray structures
provide valuable domain-level information, but key portions
of the protein remain either unresolved or missing. Iterative
homology modeling and loop building techniques can be used
to infer composite structures from their individual domains.
However, in the case of TDP-43 a suitable template structure
spanning across multiple domains does not exist, prohibiting
the ability to confidently assess the overall structure (only
an approximate schematic of the overall structure is shown,
Figure 1C) and thus the impact of the A90V and M337V
amino acid substitutions. Without a priori assumptions of the
impact of the A90V variant based on a complete model, we
then proceeded to investigate the consequences of expressing the
A90V variant on common pathological phenotypes associated
with disease: cytoplasmic relocalization, and the formation of
insoluble TDP-43 and TDP-43 protein fragments. We contrasted
the A90V variant with the well-characterized mutant M337V,
which causes autosomal-dominant familial ALS (Sreedharan
et al., 2008).
The TDP-43 A90V Variant Phenocopies
the M337V Variant by Causing
Cytoplasmic Relocalization of TDP-43
According to Winton et al. (2008b), transient expression of the
A90V variant of TDP-43 in QBI-293 cells results in the aberrant
relocalization from the nucleus to the cytoplasm. We first verified
expression of N-terminally myc-tagged TDP-43 constructs in SH-
SY5Y cells by Western blot using an N-terminal TDP-43 antibody
(Figure 2A). Steady state levels of total TDP-43 protein were
significantly increased in cells expressing M337V mutant TDP-
43 compared to WT expressing cells (0.46 ± 0.19-fold increase
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FIGURE 2 | The A90V and M337V variants of TDP-43 promote equivalent levels of cytoplasmic relocalization. (A) Western blot of total overexpressed
N-terminally myc-tagged TDP-43 WT, A90V and M337V (oe) and endogenous TDP-43 (endo). (B) Quantification of total TDP-43 levels (N = 6).
(C) Immunofluorescence staining of SH-SY5Y cells transiently transfected with WT-, A90V- or M337V-TDP-43. Cells were co-stained with anti-myc (green) and
anti-TDP-43 (red) antibodies. Nuclei were visualized with DAPI (blue). Scale bar = 30 µm. (D) Quantification of proportion of transfected cells with cytoplasmic
TDP-43 localization. Results represent mean number of cells with cytoplasmic TDP-43 ± SEM (N = 3). (E) Immunofluorescence staining of TDP-43-positive nuclear
puncta. Cells with multiple small inclusions or few larger inclusions are indicated with asterisk and arrowhead, respectively. (F) Quantification of transfected cells with
punctate nuclear TDP-43 inclusions. Results represent mean number of transfected cells with inclusions ± SEM (N = 4).∗p < 0.05 (One-way ANOVA followed by
Tukey’s multiple comparisons test).
over WT; Tukey’s multiple comparisons analysis; p = 0.04),
whereas there was no significant difference in cells expressing the
A90V TDP-43 variant compared to WT protein (0.17 ± 0.09-
fold over WT; Tukey’s multiple comparisons analysis; p = 0.57;
Figure 2B; one-way ANOVA, F2,15 = 3.757; P = 0.0316).
We confirmed that this increase in M337V TDP-43 protein
levels was not caused by increased levels of mRNA, which
were comparable between genotypes (Supplementary Figure
S1).
We then performed immunofluorescence staining
of transiently transfected cells in order to confirm the
relocalization phenotype observed by Winton et al. (2008b)
(Figures 2C,D). In agreement with the previous report
(Winton et al., 2008b), we observed a significant increase in
the proportion of cells with cytoplasmic TDP-43 localization
in A90V, compared to WT TDP-43 expressing cells (WT:
28.4 ± 3.0% of cells; A90V: 41.7 ± 3.7% of cells; Tukey’s
multiple comparisons analysis; p = 0.041). Interestingly,
the proportion of transfected cells with cytoplasmic TDP-43
localization with A90V was very similar compared to the
highly pathogenic mutant M337V (WT: 28.4 ± 3.0% of cells;
M337V: 43.0 ± 1.6% of cells; Tukey’s multiple comparisons
analysis; p = 0.028; one-way ANOVA F2,6 = 7.679; P = 0.0222;
Figure 2D).
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FIGURE 3 | TAR DNA-binding protein 43-positive nuclear puncta are
inclusions of aggregated TDP-43, and do not co-localize with
paraspeckles or nuclear stress bodies. Co-localization of TDP-43-positive
puncta with (A) paraspeckle marker polypyrimidine tract-binding
protein-associated splicing factor (PSF), (B) nuclear stress body marker
scaffold attachment factor B (SAFB), (C) ubiquitin. Left panels show
representative images of cells with numerous small nuclear puncta, right
panels cells with few, large puncta. All images shown represent
M337V-transfected cells. Wild-type (WT) and A90V-transfected cells with
puncta showed identical co-localization or lack thereof. Scale bar = 10 µm.
The M337V Mutant, but Not the A90V
Mutant, Enhances the Formation of
Nuclear TDP-43 Inclusions
In a small number of transfected cells analyzed by immuno-
fluorescence staining we detected a punctate staining pattern
for TDP-43 in the nucleus (Figure 2E). These TDP-43-
positive puncta were only rarely observed in SH-SY5Y cells
transfected with WT TDP-43 (0.28 ± 0.10% of transfected
cells), but were found in significantly higher numbers in
cells expressing the pathogenic mutant M337V (2.00 ± 0.60%
of transfected cells; Tukey’s multiple comparisons analysis;
p = 0.049; Figure 2F). However, we saw no significant difference
in puncta formation between WT and A90V TDP-43 expressing
cells (A90V: 1.06 ± 0.44% of transfected cells; Tukey’s multiple
comparisons analysis; p = 0.44; one-way ANOVA F2,9 = 3.94;
P = 0.059). In order to more closely investigate the composition
of these TDP-43-containing puncta, we performed co-staining
experiments with two nuclear markers: the nuclear stress body
marker SAFB and the paraspeckle marker PSF (Figure 3). We
qualitatively distinguished between transfected cells with small,
numerous nuclear TDP-43-positive puncta (Figure 2E, asterisk;
Figures 3A–C, lower panel) and cells with few, but large,
puncta (Figure 2E, arrowhead; Figures 3A–C, upper panel). We
observed no co-localization between TDP-43 protein and either
SAFB or PSF in small puncta (Figures 3A,B). In cells harboring
large TDP-43-positive puncta, both SAFB and PSF were found
to be excluded from these structures. We hypothesized that these
puncta represent intranuclear inclusions of insoluble, aggregated
TDP-43 protein. As aggregated TDP-43 is found pathologically
ubiquitinated (Neumann et al., 2006), we stained myc-TDP-43-
transfected cells with an anti-ubiquitin antibody (Figure 3C).
As expected, we detected diffuse ubiquitin staining in both the
nucleus and cytoplasm. Both small and large TDP-43 nuclear
puncta were shown to co-localize with ubiquitin, indicating that
they are bona fide aggregates of ubiquitinated TDP-43 protein.
The A90V TDP-43 Variant Has Subtle
Effects on Protein Solubility and
Pathologic Phosphorylation Compared
to the M337V Mutation
In order to further investigate how the A90V and M337V
mutations affect the cell biology of TDP-43, we measured a range
of cellular phenotypes which have been implicated in disease
pathogenesis. Initially, we looked at the formation of insoluble
TDP-43 aggregates. We fractionated lysates of transfected SH-
SY5Y cells into RIPA-soluble and RIPA-insoluble, urea-soluble
fractions by high speed centrifugation and separated proteins
by SDS-PAGE. We used a TDP-43 antibody recognizing the
N-terminus of TDP-43 to assess total TDP-43 protein levels
in the RIPA and urea fractions (Figure 4A). In line with
previous reports (Johnson et al., 2009; Bilican et al., 2012;
Janssens et al., 2013), we found that the M337V mutation caused
accumulation of insoluble TDP-43 in the urea fraction compared
to WT (3.21 ± 1.14-fold increase over WT; Tukey’s multiple
comparisons analysis; p = 0.023; one-way ANOVA F2,9 = 5.38;
P = 0.029). While an enrichment of TDP-43 in the urea fraction
was also observed in A90V-expressing cells (1.59 ± 0.38-fold
increase compared to WT), the increase was not statistically
significant (Tukey’s multiple comparisons analysis; p = 0.283;
Figure 4B).
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FIGURE 4 | The A90V TDP-43 variant has subtle effects on protein solubility and phosphorylation compared to the M337V variant. (A) Western blot of
total TDP-43 (N-terminal antibody) and phospho-S409/S410 TDP-43 in radio-immunoprecipitation assay (RIPA)-soluble (R) and RIPA-insoluble, urea-soluble (U)
fractions. (B,C), Western blot quantification of (B) total TDP-43 and (C) phospho-TDP-43 normalized to total TDP-43 in insoluble fractions. All results represent
mean band signal ± SEM. ∗p < 0.05 (N = 4, One-way ANOVA followed by Tukey’s multiple comparisons test).
We used a phospho-specific TDP-43 antibody raised
against the disease-relevant phosphorylation sites at S409/S410
(Neumann et al., 2009) to assess the phosphorylation status
of the insoluble TDP-43 protein species (Figure 4A). We
normalized the phospho-signal in the urea-soluble fractions
to the total TDP-43 detected in these fractions to control for
the relative increase in insoluble TDP-43 protein in mutant
expressing cells (Figure 4C). Immunoblotting with this antibody
revealed significantly increased phosphorylation levels at the
S409/S410 residues in the urea-soluble fraction of M337V
TDP-43 expressing cells compared to cells expressing WT
TDP-43 (6.38 ± 2.56-fold increase compared to WT; Tukey’s
multiple comparisons analysis; p = 0.036). We detected a non-
statistically significant increase in S409/S410 phosphorylation
in cells transfected with the A90V variant (1.35 ± 0.48-fold
increase compared to WT; Tukey’s multiple comparisons
analysis; p = 0.80; one-way ANOVA F2,9 = 5.015; P = 0.0344).
Taken together, these results indicate that while the A90V
and M337V mutations induce similar levels of cytoplasmic
relocalization of TDP-43, a pathology commonly associated
with disease, the effects of the M337V variant on protein
solubility and phosphorylation are far greater than those of
the A90V mutation. In fact there looks to be a spectrum
of pathology in these transfected cell models with WT and
M337V TDP-43 at the opposite extremes, with the A90V
TDP-43 somewhere in between, in the absence of any additional
stressors.
M337V Mutant TDP-43 Readily Forms
C-Terminal Fragments Compared to
A90V and WT
In addition to abnormal phosphorylation as well as decreased
protein solubility and aberrant cellular localization, another
pathological feature of TDP-43 is the formation of C-terminal
truncated protein fragments (Neumann et al., 2006; Mackenzie
et al., 2007; Hasegawa et al., 2008). In order to detect C-terminal
protein fragments not picked up by the N-terminal TDP-43
antibody used in Figure 4 we extracted soluble and insoluble
TDP-43 from transfected SH-SY5Y cells and used a C-terminal
antibody (Figures 5A,B). We identified two smaller protein
species present only in TDP-43-transfected cells, but not in the
vector control cells (Figure 5B). The larger fragment ran close to
the 34 kDa marker, while the smaller fragment ran close to the
26 kDa marker. C-terminal TDP-43 fragments with molecular
weights of 35 kDa (CTF35) and 25 kDa (CTF25) have been
described in a variety of cellular and animal models (Winton
et al., 2008a; Xu et al., 2011; Bilican et al., 2012; Choksi et al.,
2014; D’Alton et al., 2014; Li et al., 2015), and we will thus
refer to the identified truncated TDP-43 species as CTF35 and
CTF25. We quantified the amount of both fragments in the RIPA-
soluble and urea-soluble fractions. We normalized to the amount
of full-length TDP-43 in each sample in order to account for the
increase of total TDP-43 protein. In the RIPA-soluble fraction,
we observed an accumulation of CTF35 in M337V-transfected
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FIGURE 5 | The M337V TDP-43 variant readily forms C-terminal fragments compared to A90V and WT. (A,B) Western blot of TDP-43 with C-terminal
antibody for detection of C-terminal fragment. (A) short exposure, (B) longer exposure revealing 35 kDa fragment (CTF35) and 25 kDa fragment (CTF25). (C,D)
Western blot quantification of TDP-43 fragment CTF35 (C) and CTF25 (D) (red boxes indicate quantified bands). All results represent mean band signal ± SEM.
∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 (N = 3, One-way ANOVA followed by Tukey’s multiple comparisons test).
cells compared to either WT or A90V-TDP-43 (2.03 ± 0.44-
fold increase over WT, p = 0.005; 0.68 ± 0.25-fold increase over
A90V, p= 0.044; Tukey’s multiple comparisons analysis; one-way
ANOVA F2,6 = 13.94; P = 0.0056; Figure 5C). However, we did
not detect a significant increase of the smaller CTF25 in mutant-
transfected cells (M337V: 1.09 ± 0.6-fold increase over WT,
p = 0.19; 0.64 ± 0.52-fold increase over A90V, p = 0.36; Tukey’s
multiple comparisons analysis; one-way ANOVA F2,6 = 2.166;
P = 0.196). In the urea-soluble fractions the effect of the M337V
mutant on the formation of these C-terminal fragments was
even more striking: we detected a 20.0 ± 6.6-fold increase
in the 25 kDa fragment in the M337V mutant compared to
WT (Tukey’s multiple comparisons analysis; p = 0.026) and a
4.3 ± 1.7-fold increase compared to the A90V variant (Tukey’s
multiple comparisons analysis; p = 0.049; one-way ANOVA
F2,6 = 7.657; P = 0.0223; Figure 5D). We could not detect any
35 kDa fragment in the urea fraction of WT-TDP-43 transfected
cells and found a 5.4 ± 1.1-fold increase in CTF35 levels in
M337V- compared to A90V-transfected cells (M337V compared
to WT: p = 0.0008: compared to A90V: p = 0.0019; Tukey’s
multiple comparisons analysis; one-way ANOVA F2,6 = 31.53;
P = 0.0007).
The M337V TDP-43 Variant
Down-regulates the Expression of G3BP
and HDAC6
We hypothesized that the M337V mutant of TDP-43 not only
impacts TDP-43 localization and post-translational modifications
in a manner more detrimental than the A90V variant, but that the
downstream functional consequences of expressing M337V TDP-
43 might reflect this more severe phenotype. Such a functional
consequence could be altered regulation of transcriptional targets
of TDP-43. Previous studies have shown that both depletion
of endogenous TDP-43 as well as overexpression of R361S
mutant TDP-43 lead to a decrease in G3BP, a regulator of stress
granule assembly (McDonald et al., 2011; Aulas et al., 2012). We
investigated expression levels of G3BP following 48 h of TDP-
43 overexpression and found that only M337V, but not A90V,
mutant TDP-43 significantly downregulated G3BP compared to
WT TDP-43 and mock control (25.8 ± 8.3% compared to WT,
p = 0.01; 23.0 ± 7.8% compared to mock, p = 0.03; Tukey’s
multiple comparisons analysis; one-way ANOVA F3,20 = 4.861;
P = 0.0106; Figures 6A,C). Furthermore, levels of HDAC6, a
known target of TDP-43 that is likewise downregulated upon
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FIGURE 6 | The M337V, but not the A90V variant, leads to a downregulation of G3BP and HDAC6. Western blots of (A) G3BP, (B) HDAC6 and acetylated
α-tubulin levels in SH-SY5Y cells expressing WT, A90V and M337V TDP-43 or cells transfected with myc control vector. (C–E) Densitometry analyses of (C) G3BP
(N = 6), (D) HDAC6 (N = 4), and (E) acetylated α-tubulin levels (N = 6). All results represent mean band signal ± SEM. ∗p < 0.05, ∗∗p < 0.01 (One-way ANOVA
followed by Tukey’s multiple comparisons test).
TDP-43 silencing (Fiesel et al., 2010), were significantly reduced
in M337V TDP-43 expressing cells compared to cells transfected
with WT and A90V TDP-43 or mock-transfected controls (WT:
36.1 ± 13.6%; p = 0.017; A90V: 35.6 ± 12.3%; p = 0.02; mock:
43.0 ± 10.2%; p = 0.002; Tukey’s multiple comparisons analysis;
one-way ANOVA F3,12 = 8.455; P = 0.0027; Figures 6B,D).
We also probed for levels of acetylated α-tubulin, a substrate
for HDAC6 (Hubbert et al., 2002), but found no significant
increase in acetylated α-tubulin levels in M337V-transfected cells
compared to WT (p= 0.99) or A90V (p= 0.99) TDP-43 (Tukey’s
multiple comparisons analysis; Figures 6B,E), suggesting that the
decrease in HDAC6 protein levels in M337V-expressing cells is
not sufficient to impair acetylation of α-tubulin. In comparison
to mock-transfected controls, both WT and A90V-transfected
cells showed a small, but significant upregulation of acetylated
α-tubulin (WT: 15.8 ± 4.5%, p = 0.05; A90V: 16.0 ± 3.8%,
p = 0.04; Tukey’s multiple comparisons analysis) and M337V-
transfected cells showed a similar trend (14.2 ± 5.2%, p = 0.08;
one-way ANOVA F3,20 = 3.833; P = 0.0256). An increase
in α-tubulin acetylation has been described in conditions of
cellular stress (Mackeh et al., 2014), which could be caused
by the overexpression of TDP-43 irrespective of mutation. In
conclusion, the M337V variant of TDP-43, but not the A90V
variant, impacted the expression of known targets of TDP-43 in
a manner consistent with the effects of a knockdown of TDP-43
function.
DISCUSSION
To date, genetic studies have revealed 52 missense mutations in
the TDP-43 gene TARDBP as well as one insertion/deletion and
one nonsense mutation (Buratti, 2015). While most mutations
cluster in the C-terminal glycine-rich domain, the A90V amino
acid exchange lies in the bipartite NLS. The pathogenic nature
of this variant remains uncertain; in vitro studies suggest that
A90V-TDP-43 is more prone to cytoplasmic mislocalization and
aggregation, two pathological changes associated with ALS and
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FTD (Winton et al., 2008b). Furthermore, expression of A90V
TDP-43 fails to fully ameliorate the pupal lethality and neuronal
loss phenotypes caused by loss of the Drosophila ortholog of
TARDBP (Vanden Broeck et al., 2015). Genetic studies, however,
have revealed the presence of the A90V variant both in patients
suffering from ALS and FTD as well as in healthy controls
(Guerreiro et al., 2008; Kabashi et al., 2008; Sreedharan et al.,
2008; Winton et al., 2008b; Chiang et al., 2012). It is thus likely
that A90V is not a highly penetrant disease-associated mutation,
but a genetic risk factor for TDP-43 proteinopathies. In order
to gain a deeper understanding of the pathogenic potential of
the A90V variant, we initially conducted analyses of available
structural information for TDP-43 to see if we could generate
hypotheses to test based on the site of the mutations. But
unfortunately, due to the lack of complete NMR and X-ray
structures, we were unable to predict the impact of the A90V
variant of TDP-43 in silico (Figure 1). We then resorted to more
traditional in vitro studies to measure TDP-43 mislocalization,
changes in protein solubility and phosphorylation, and the effects
on their expression on known targets of TDP-43. We compared
the impact of A90V with that of the M337V mutation, a disease-
associated mutation frequently used for in vitro and in vivo
studies of ALS pathogenesis (Liachko et al., 2010; Zhou et al.,
2010; Bilican et al., 2012; Janssens et al., 2013; Mutihac et al.,
2015).
When we initially looked to reproduce the nuclear localization
phenotype observed by Winton et al. (2008b) we found an
almost identical increase in the number of cells with cytoplasmic
TDP-43 with both the A90V and M337V variants. Thus, we
concluded that the A90V variant of TDP-43 phenocopies the
cytoplasmic relocalization phenotype associated with ALS found
in the disease-associated M337V mutant. This strong effect is
perhaps not surprising given the fact that the A90V variant lies
within the bipartite NLS and could thus potentially interfere with
nucleo-cytoplasmic shuttling of TDP-43.
In a small subset of transfected cells, we detected dot-like
structures in the nucleus that stained positive for TDP-43.
These TDP-43-positive nuclear structures were observed more
frequently in cells transfected with the M337V, but not the
A90V, mutant compared to WT. Instances of defined, patterned
nuclear staining of TDP-43 in vitro have been described in
the literature: overexpression of certain deletion mutants or the
M337V mutant has been shown to cause the formation of nuclear
inclusions of aggregated TDP-43 (Winton et al., 2008a; Nonaka
et al., 2009a; Tripathi et al., 2014), while other papers describe
co-localization of TDP-43 with nuclear bodies under certain
circumstances, such as stress bodies under heat shock conditions,
or NEAT1_2-containing paraspeckles (Nishimoto et al., 2013;
Udan-Johns et al., 2014). We sought to define the nature of
the observed nuclear TDP-43-positive puncta by performing
co-localization experiments using antibodies against SAFB as
a marker of nuclear stress bodies and PSF as a paraspeckle
marker. We did not observe co-localization of either SAFB or
PSF with TDP-43-positive inclusions, indicating that WT and
mutant TDP-43 are not recruited into nuclear stress bodies or
paraspeckles. However, we found that nuclear puncta of TDP-43
co-stain with ubiquitin, suggesting that they represent inclusions
of aggregated, ubiquitinated TDP-43 in the nucleus. In this light,
the increased frequency of these TDP-43-positive inclusions in
the M337V mutant is probably the result of a higher aggregation
propensity.
We investigated the aggregation propensity of the A90V and
M337V mutants further by sequential extraction of total cell
lysates. We found a stark increase in M337V in the insoluble
fraction, in line with published literature showing increased
aggregate formation of M337V-TDP-43 in vitro, in vivo, and in
culture systems (Johnson et al., 2009; Zhou et al., 2010; Bilican
et al., 2012). Compared to WT protein, the increase we observed
in insoluble A90V TDP-43 was not statistically significant.
Phosphorylation levels of insoluble, aggregated TDP-43 species at
the pathologically relevant S409/410 residues were also markedly
increased in the M337V mutant, while the effect in the A90V
mutant was modest and not statistically significant. Analysis of
total unfractionated lysate also revealed a significant increase in
total mutant M337V TDP-43 protein compared to WT, likely
due to the longer half-life of M337V-TDP-43 previously reported
(Ling et al., 2010; Watanabe et al., 2013). While this increase in
total M337V mutant protein could possibly help drive some of the
described phenotypes, we believe the modest effect size (less than
50% compared to WT, less than 20% compared to A90V) is not
sufficient to cause some of the more striking phenotypes we have
observed, such as the effects on G3BP and HDAC6 expression
levels.
C-terminally cleaved TDP-43 fragments are another
pathological hallmark of ALS and FTD, and expression of
TDP-43 in cell culture models can give rise to cleavage products
of 35 and 25 kDa in the absence or presence of various stressors
(Neumann et al., 2006; Hasegawa et al., 2008; Chiang et al., 2012;
Yang et al., 2014; Li et al., 2015). We found an enrichment of
two fragments of approximately 35 and 25 kDa in the insoluble
fraction of M337V-transfected cells compared to both WT and
A90V. Almost no C-terminal fragments were detected in the
insoluble fraction of A90V-transfected cells, suggesting that
A90V-TDP-43 is less prone to protease cleavage compared to
the familial ALS mutant M337V. This phenotype is especially
striking as several papers have suggested a crucial role for
C-terminal TDP-43 fragments in enhancing cellular toxicity and
aggregation propensity, especially the 25 kDa fragment (Johnson
et al., 2008; Nonaka et al., 2009b; Zhang et al., 2009; Kitamura
et al., 2016).
In addition to the effects of the A90V variant on TDP-43
aggregation, post-translational modifications and truncation, we
investigated changes in known targets of TDP-43. We found
that protein levels of G3BP are reduced in SH-SY5Y cells
expressing M337V, but not A90V TDP-43. G3BP is a component
of cytoplasmic stress granules, transient structures made from
proteins and untranslated mRNAs, which form after insults such
as heat shock and oxidative stress (Nover et al., 1989; Tourriere
et al., 2003). Similarly, we found that only the M337V, but not
the A90V mutant, leads to a reduction of the histone deacetylase
HDAC6 in SH-SY5Y cells; HDAC6 has previously been claimed
to be a critical component of stress granule assembly (Kwon
et al., 2007). TDP-43 has been shown to be both recruited to and
to regulate assembly of stress granules (Colombrita et al., 2009;
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McDonald et al., 2011). That the A90V variant of TDP-43, in
contrast to the M337V variant, does not cause a downregulation
of G3BP or HDAC6 could suggest that A90V does not interfere
with stress granule assembly and dynamics, while the disease-
associated M337V mutant does. In this regard, the M337V
mutant causes a loss of normal function of TDP-43 regulation
of stress granule assembly – while the A90V variant does
not. Structurally, stress granules are protein-rich liquid droplets
formed in a process termed liquid-liquid phase separation
(LLPS). Recent studies have shown that mutations in the
C-terminal domain, including the M337V mutation, inhibit this
droplet formation by interrupting the interaction of α-helixes,
driving the proteins to form aggregates instead (Molliex et al.,
2015; Conicella et al., 2016; Schmidt and Rohatgi, 2016). Since the
A90V variant is far removed from the α-helix in the C-terminal
domain, it is likely that it does not interfere with the helical
contact that drives droplet formation. However, further studies
will be required to investigate whether A90V has more subtle
effects on TDP-43 LLPS, droplet formation, and stress granule
assembly.
In summary, the results of this study show that the A90V
variant of TDP-43, which has been described as a rare variant
found both in ALS and FTD patients and healthy controls,
shows modest effects on protein solubility, phosphorylation,
and truncation when compared to the disease-causing M337V
mutation. In addition, in contrast to the M337V mutant,
the A90V variant does not cause impairment of HDAC6 or
G3BP expression. These findings are especially striking since we
observed comparable levels of cytoplasmic TDP-43 relocalization
in both A90V- and M337V-transfected cells, suggesting that
cytoplasmic relocalization of TDP-43 protein is not by itself
sufficient to cause the other molecular phenotypes associated
with disease. Furthermore, we speculate that due to these
modest in vitro effects observed with the A90V variant, carriers
might not develop a disease phenotype in the absence of a
“second hit.” However, it is possible that the A90V mutant
could lower the threshold required for an additional stressor
or other genetic risk factor to cause the catastrophic effects on
TDP-43 and its functions observed in ALS and FTD. Thus,
we conclude that the A90V variant of TDP-43 could be a
rare genetic risk factor for TDP-43 proteinopathies. However,
further studies will be required to gain an insight into the
interplay between A90V as a genetic risk factor and other
genetic and environmental risk factors associated with ALS and
FTD.
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